STADA Letrozole(Femara)2.5mg Bodybuilding CAS:112809-51-5
Letrozole (brand name Femara) is a potent, non-steroidal aromatase inhibitor (AI) originally developed for treating hormone-receptor-positive breast cancer in postmenopausal women. It functions by binding irreversibly to the aromatase enzyme, blocking the conversion of androgens (e.g., testosterone) into estrogen.
What is Letrozole?
Letrozole (brand name Femara) is a potent, non-steroidal aromatase inhibitor (AI) originally developed for treating hormone-receptor-positive breast cancer in postmenopausal women. It functions by binding irreversibly to the aromatase enzyme, blocking the conversion of androgens (e.g., testosterone) into estrogen. This mechanism reduces systemic estrogen levels by up to 98%, making it one of the strongest AIs available. In bodybuilding, it is used off-label to counteract estrogenic side effects from aromatizable anabolic steroids.
Key Features
●Potency: Letrozole suppresses estrogen more aggressively than other AIs (e.g., Anastrozole), often achieving near-total aromatase inhibition.
●Non-Steroidal Structure: Unlike steroidal AIs (e.g., Exemestane), it lacks hormonal activity, minimizing androgenic/progestogenic side effects.
●Oral Bioavailability: Administered orally, with rapid absorption (peak plasma concentration in 2 hours).
●Selective Action: Targets aromatase exclusively without interfering with cortisol or aldosterone synthesis.
●Reversible Effects: Estrogen rebound can occur post-discontinuation due to its reversible enzyme binding.
Applications in Bodybuilding
Letrozole is used strategically-not as a muscle-builder-to manage estrogen during cycles:
●Gynecomastia Prevention: Blocks estrogen-triggered breast tissue growth.
●Water Retention Control: Reduces subcutaneous fluid, enhancing muscle definition.
●Lipid Metabolism: Mitigates estrogen-induced cholesterol imbalances (e.g., low HDL).
●Post-Cycle Therapy (PCT) Support: Occasionally used to kickstart endogenous testosterone before SERMs (e.g., Clomid), though controversially due to its potency.
Perceived Benefits
●Estrogen Management: Rapidly resolves gynecomastia symptoms (e.g., nipple sensitivity) within days.
●Muscle Hardness: By reducing water retention, muscles appear denser and more vascular.
●Synergy with Steroids: Allows higher androgen doses without estrogenic sides, potentially amplifying gains.
●Minimal Androgenic Impact: Unlike Proviron or Masteron, it doesn't convert to DHT.
Caveat: Benefits are secondary to its estrogen-suppressing role-it does not directly enhance anabolism.
Dosage & Administration
Medical Dose: 2.5mg/day for cancer treatment.
Bodybuilding Protocol:
●Preventive Use: 0.25–0.5mg 2–3x/week.
●Acute Gynecomastia: 0.5–1mg/day for 7–14 days (taper upon symptom resolution).
●Maximum Duration: 4–6 weeks to avoid severe side effects.
Critical Notes:
●Tablets are split (e.g., quarters of 2.5mg pill = 0.625mg) for precision dosing.
●Bloodwork (estradiol, lipids, testosterone) is mandatory before/during use.
Cycle Integration
●Bulking Cycles: Paired with aromatizable steroids (e.g., Testosterone Enanthate, Dianabol).
○Sample Protocol:
◇Weeks 1–12: Testosterone (500mg/week) + Letrozole (0.25mg EOD).
◇Adjust dose if E2 falls below 20 pg/mL (risk of joint pain/libido loss).
●Contest Prep: Used in the final 4 weeks (0.5mg EOD) to eliminate water weight.
●Avoid Monotherapy: Never used solo-only alongside androgens to prevent estrogen crash.
Half-Life & Pharmacokinetics
●Half-Life: 2–4 days (steady state in ~10 days).
●Metabolism: Liver (CYP3A4/CYP2A6 enzymes), excreted renally.
●Dosing Frequency: Due to long half-life, dosing every 2–3 days suffices for most users.
Role in Post-Cycle Therapy (PCT)
●Controversial Utility: Some protocols use low-dose Letrozole (0.25mg EOD) for the first 7–10 days of PCT to block residual estrogen and amplify gonadotropin release.
●Risks: Overuse suppresses estrogen excessively, impairing HPTA recovery.
●Standard PCT Alternative: SERMs (e.g., Tamoxifen) remain first-line for testosterone restoration.
Risks & Side Effects
●Estrogen Crash Symptoms:
○Joint pain, dry eyes, insomnia, depression, and tendon injuries (due to collagen loss).
●Cardiovascular: Lowers HDL ("good" cholesterol) by 20–30%, increasing atherosclerosis risk.
●Bone Health: Prolonged use may reduce bone mineral density.
●Endocrine Disruption: Suppressed estrogen can cause hypogonadism, requiring TRT post-cycle.
●Hepatotoxicity: Rare, but elevated liver enzymes reported at high doses.
Contraindications: Pre-existing heart disease, osteoporosis, or pregnancy (Category X teratogen).
Clinical Data
|
Brand |
STADA |
|
Trade names |
Femara,letrozole |
|
CAS |
112809-51-5 |
|
Molar mass |
285.310 |
| Formula |
C17H11N5 |
|
Purity |
Above 98% |
|
Apprarance |
25mg*50 |
Any needs, please contact us
Email: Jasonraws106@gmail.com
WhatsApp: +86-15572565525
Telegram: +86-19128233885
Conclusion: A Double-Edged Sword
Letrozole is a nuclear option for estrogen control in bodybuilding-effective but perilous. Its extreme potency demands respect: microdosing (0.25–0.5mg) and short durations are non-negotiable. While it excels in resolving acute gynecomastia or water retention, its side-effect profile overshadows benefits for casual users. Always prioritize:
●Regular blood tests (estradiol, lipids).
●Concurrent liver support (e.g., TUDCA).
●Post-cycle health evaluations (bone density, cardiac markers).
For sustainable bodybuilding, milder AIs and SERMs remain preferable, reserving Letrozole for emergencies. Never self-prescribe; consult an endocrinologist familiar with sports medicine.
Hot Tags: stada letrozole(femara)2.5mg bodybuilding cas:112809-51-5, China stada letrozole(femara)2.5mg bodybuilding cas:112809-51-5 manufacturers, suppliers, factory
